CN113324933B - Method for detecting angiotensin converting enzyme and application thereof - Google Patents
Method for detecting angiotensin converting enzyme and application thereof Download PDFInfo
- Publication number
- CN113324933B CN113324933B CN202110611018.5A CN202110611018A CN113324933B CN 113324933 B CN113324933 B CN 113324933B CN 202110611018 A CN202110611018 A CN 202110611018A CN 113324933 B CN113324933 B CN 113324933B
- Authority
- CN
- China
- Prior art keywords
- cys
- ace
- aunps
- ang
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
- G01N21/314—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry with comparison of measurements at specific and non-specific wavelengths
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/38—Diluting, dispersing or mixing samples
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/47—Scattering, i.e. diffuse reflection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
- G01N23/02—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by transmitting the radiation through the material
- G01N23/04—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by transmitting the radiation through the material and forming images of the material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
- G01N21/314—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry with comparison of measurements at specific and non-specific wavelengths
- G01N2021/3155—Measuring in two spectral ranges, e.g. UV and visible
Abstract
The invention discloses a method for detecting angiotensin converting enzyme and application thereof, wherein ACE is diluted in deionized water to a final concentration of 0.5mU/L to 60mU/L, each 96-pore plate contains 25 mU L of ACE and 40mU L of 5mU M Cys-ang (I) -Cys peptide, incubation is carried out at 37 ℃, then 50 mU L AuNPs is added into the 96-pore plate, an ACE activity signal is amplified by detecting the residual amount of the Cys-ang (I) -Cys peptide, and finally the ultraviolet visible absorption spectrum of the AuNPs solution in the range of 400-800nm is recorded within 5 min. The invention designs a Cys-Ang (I) -Cys peptide based on angiotensin I, wherein each end of the Cys-Ang (I) -Cys peptide is connected with a cysteine (Cys), the Cys-Ang (I) -Cys peptide can be gathered on the surfaces of AuNPs at two ends through Au-S bonds and stimulates the gathering of the AuNPs to be purple or blue, the Cys-Ang (I) -Cys peptide is hydrolyzed after ACE is introduced, and sulfydryl is dissociated from one end of the peptide to cause the AuNPs to be dispersed and red, and the ACE detection is carried out in a rapid and direct mode by realizing the hydrolysis of ACE catalytic peptide and the assembly/decomposition of the AuNPs mediated by the peptide, and the method is operated to screen ACE inhibitors or inhibitory peptides.
Description
Technical Field
The invention relates to the technical field of angiotensin converting enzyme activity detection, in particular to a method for detecting angiotensin converting enzyme and application thereof.
Background
Angiotensin Converting Enzyme (ACE) plays a dominant role in the regulation of blood pressure in the renin-angiotensin system, the product of which directly affects the pathogenesis of cardiovascular disease (CVD). ACE is essentially a class of zinc-dependent peptidases that hydrolyze angiotensin (Ang) I to angiotensin II, which is further cleaved by ACE2 to form shorter Ang- (1-7) peptides.
In addition to angiotensin I, ACE hydrolyzes many other polypeptides, such as substance P, enkephalin and bradykinin, affecting many physiological processes such as reproduction, renal metabolic function, hematopoiesis, and immune response. Increased ACE activity leads to the production of large amounts of angiotensin II, a potent vasoconstrictor that makes hypertension a possible and therefore ACE is a potential target for antihypertensive drugs. ACE consists of two independent catalytic domains with different biological functions, and an inhibitor aiming at a specific domain of the ACE is developed into an effective antihypertensive drug which is proved to have a strong antihypertensive effect. ACE inhibitors, such as food derived peptides, are being developed that are safer and more beneficial to human health. Therefore, efficient and rapid detection of ACE levels in human serum is crucial for the prevention of hypertension and the discovery of novel inhibitors.
Traditional methods of measuring ACE activity rely primarily on fluorometric assays, where ACE catalyzes the hydrolysis of a particular substrate to produce a fluorogenic substrate, and spectrophotometric assays to determine the amount of hydrolysate produced. Other methods based on High Performance Liquid Chromatography (HPLC) and mass spectrometry have also been developed. However, most methods of detecting ACE have limited reliability and sensitivity. More importantly, the large reagent requirements, complex operations and advanced instrumentation limit their use in some resource-poor environments. Therefore, there is an urgent need to develop a simple and effective Angiotensin Converting Enzyme (ACE) detection technique, which is of great value in biomedical diagnosis. Rapidly evolving nanotechnology offers a promising platform for the development of biosensing technologies to address these challenges. The unique phenomenon and extraordinary performance of nanostructures on the nanometer scale is an important aid to the performance of biosensors. One notable material is plasmonic gold nanoparticles (AuNPs), which have been widely used in biomedical analysis due to their unique surface chemistry, electronic and tunable optical properties. The plasma sensor based on AuNPs can be effectively, simply and conveniently read by naked eyes without the help of advanced instruments, which brings huge prospect to various biological analysis methods in biomedical diagnosis.
Disclosure of Invention
In order to overcome the above-mentioned defects of the prior art, the embodiments of the present invention provide a method for detecting angiotensin converting enzyme and applications thereof, and the technical problems to be solved by the present invention are: the activity of the angiotensin converting enzyme can be detected more simply, conveniently and effectively.
In order to achieve the purpose, the invention provides the following technical scheme: a method for detecting angiotensin converting enzyme, when detecting ACE activity, diluting ACE in deionized water to final concentration from 0.5mU/L to 60mU/L, each 96-well plate contains ACE 25 mU L, Cys-ang (I) -Cys peptide 40mU L, incubating at 37 ℃, then adding 50 mU L AuNPs in 96-well plate, amplifying ACE activity signal by detecting residual amount of Cys-ang (I) -Cys peptide, and finally recording ultraviolet visible absorption spectrum of AuNPs solution in 400-800nm range within 5 min;
before the ACE activity is detected, AuNPs need to be synthesized, and the synthesis method of the AuNPs comprises the following steps:
100 ml of 1mM chloroauric acid was weighed into a round-bottom flask, heated to 120 ℃ by continuous stirring, then 10 ml of 38.8mM sodium citrate solution was added rapidly and continuously to ensure complete reduction of chloroauric acid, which means formation of AuNPs when the solution turned from colorless to deep red, and the heat was removed and the AuNPs were cooled at room temperature until use.
In a preferred embodiment, before the ACE activity is detected, aggregation of AuNPs is induced by Cys-Ang (I) -Cys peptide, different concentrations of Cys-Ang (I) -Cys peptide are added into 150 μ L deionized water, 50 μ L AuNPs are added, after 5 minutes of equilibration, the AuNPs solution is aggregated to different degrees due to Au-S interaction, the color of the AuNPs solution changes from red to blue or purple with the increase of the concentration of Cys-Ang (I) -Cys peptide, and the solution is further analyzed and characterized by ultraviolet-visible spectroscopy, dynamic light scattering and transmission electron microscopy, so that the concentration of Cys-Ang (I) -Cys peptide added into each 96-well plate is determined to be 5 μ M.
In a preferred embodiment, the incubation time at 37 ℃ for 30 minutes to ensure adequate hydrolysis of the Cys-Ang (I) -Cys peptide when detecting ACE activity.
In a preferred embodiment, the larger impurities in AuNPs are removed by using a polyethersulfone membrane after a heat source is removed and the AuNPs required by experiments are removed after cooling in the ACE synthesis process.
In a preferred embodiment, the amount of Cys-Ang (I) -Cys peptide added when inducing aggregation of AuNPs using Cys-Ang (I) -Cys peptide is 50. mu.L, ensuring a final volume of 250. mu.L in a 96-well plate with different concentrations of Cys-Ang (I) -Cys peptide in the range of 0-1000 nM.
The invention also provides an application of the method for detecting the angiotensin converting enzyme,
(I): detecting ACE inhibitor, mixing 40mu L of ACE with 40mu L of enalapril and ramipril with different concentrations, incubating at 37 ℃, adding 40mu L of Cys-Ang (I) -Cys peptide and 30mu L of deionized water, testing the residual ACE activity according to the method for detecting ACE activity, then adding 50 mu L of AuNPs as a signal amplification tool, and detecting ACE inhibition activity by adopting 400-800nm AuNPs ultraviolet visible absorption spectrum;
(II): screening ACE inhibitory peptides, incubating 9 different active peptides with 30mU/mL ACE in deionized water for 15 min, adding 5 μ M Cys-Ang (I) -Cys to react with inactivated ACE at 37 deg.C for 15 min, adding 50 μ L AuNPs to 150 μ L mixture, and screening out polypeptides with ACE inhibitory activity by color change.
In a preferred embodiment, the incubation time for detection of ACE inhibitors is 20 minutes at 37 ℃ to ensure adequate inhibition of ACE activity.
In a preferred embodiment, when the ACE inhibitory peptides are screened, the peptides with ACE inhibitory function can induce aggregation of AuNPs and have purple color, while the peptides without ACE inhibitory function can not induce aggregation of AuNPs and have red color; the 9 different active peptides were KAFAF, CAAAA, VPP, IPP, RPP, IPA, LEP, LQP and GSH, respectively, and the concentrations of the 9 active peptides were all 15 μ M.
Compared with the prior art, the invention has the following technical effects and advantages:
the invention designs a Cys-Ang (I) -Cys peptide based on angiotensin I, wherein each end of the Cys-Ang (I) -Cys peptide is connected with a cysteine (Cys), the Cys-Ang (I) -Cys peptide can be gathered on the surfaces of AuNPs at two ends through Au-S bonds and stimulates the gathering of the AuNPs to be purple or blue, the Cys-Ang (I) -Cys peptide is hydrolyzed after ACE is introduced, and sulfydryl is dissociated from one end of the peptide to cause the AuNPs to be dispersed and red, and the ACE detection is carried out in a rapid and direct mode by realizing the hydrolysis of ACE catalytic peptide and the assembly/decomposition of the AuNPs mediated by the peptide, and the method is operated to screen ACE inhibitors or inhibitory peptides.
Drawings
FIG. 1 is a schematic representation of the detection of angiotensin converting enzyme activity and inhibitors or inhibitory peptides according to the present invention;
FIG. 2 is a diagram illustrating the linear range of ACE detection according to the present invention;
FIG. 3 is a graph showing the results of the Ramipril inhibitory rate assay according to the present invention.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be obtained by a person skilled in the art without making any creative effort based on the embodiments in the present invention, belong to the protection scope of the present invention.
As shown in figure 1, in the method for detecting angiotensin converting enzyme, when the ACE activity is detected, ACE is diluted in deionized water to a final concentration of 0.5mU/L to 60mU/L, each 96-well plate contains ACE 25 mU L, Cys-ang (I) -Cys peptide 40mU L, incubation is carried out at 37 ℃, then 50 mU L AuNPs are added into the 96-well plate, an ACE activity signal is amplified by detecting the residual quantity of the Cys-ang (I) -Cys peptide, and finally the ultraviolet visible absorption spectrum of the AuNPs solution in the range of 400-800nm is recorded within 5 min;
before the ACE activity is detected, AuNPs need to be synthesized, and the synthesis method of the AuNPs comprises the following steps:
100 ml of 1mM chloroauric acid was weighed into a round-bottom flask, heated to 120 ℃ by continuous stirring, then 10 ml of 38.8mM sodium citrate solution was added rapidly and continuously to ensure complete reduction of chloroauric acid, which when the solution turned from colorless to deep red, indicated the formation of AuNPs, the heat was removed and the AuNPs were cooled at room temperature and ready for use.
In a preferred embodiment, before the ACE activity is detected, aggregation of AuNPs is induced by Cys-Ang (I) -Cys peptide, different concentrations of Cys-Ang (I) -Cys peptide are added into 150 μ L deionized water, 50 μ L AuNPs are added, after 5 minutes of equilibration, the AuNPs solution is aggregated to different degrees due to Au-S interaction, the color of the AuNPs solution changes from red to blue or purple with the increase of the concentration of Cys-Ang (I) -Cys peptide, and the solution is further analyzed and characterized by ultraviolet-visible spectroscopy, dynamic light scattering and transmission electron microscopy, so that the concentration of Cys-Ang (I) -Cys peptide added into each 96-well plate is determined to be 5 μ M.
In a preferred embodiment, the incubation time at 37 ℃ for 30 minutes to ensure adequate hydrolysis of the Cys-Ang (I) -Cys peptide when detecting ACE activity.
In a preferred embodiment, the heat source is removed during the ACE synthesis process, and after cooling, a polyethersulfone membrane is used for removing larger impurities in AuNPs to obtain AuNPs required by experiments.
In a preferred embodiment, the amount of Cys-ang (I) -Cys peptide added when inducing aggregation of AuNPs with Cys-ang (I) -Cys peptide is 50. mu.L, ensuring a final volume of 250. mu.L in a well of 96-plate with the concentration of Cys-ang (I) -Cys peptide in the well of 96-plate ranging from 0 to 1000 nM.
The invention also provides an application of the method for detecting the angiotensin converting enzyme,
(I): detecting ACE inhibitor, mixing 40 μ L ACE with 40 μ L enalapril and ramipril with different concentrations, incubating at 37 deg.C, adding Cys-Ang (I) -Cys peptide 40 μ L and deionized water 30 μ L, testing the rest ACE activity according to the method for detecting ACE activity, adding 50 μ L AuNPs as signal amplification tool, and detecting the ACE inhibitory activity by adopting 400-800nm AuNPs ultraviolet-visible absorption spectrum;
(II): screening ACE inhibitory peptides, incubating 9 different active peptides with 30mU/mL ACE in deionized water for 15 min, adding 5 μ M Cys-Ang (I) -Cys to react with inactivated ACE at 37 deg.C for 15 min, adding 50 μ L AuNPs to 150 μ L mixture, and screening out polypeptides with ACE inhibitory activity by color change.
In a preferred embodiment, the assay for ACE inhibitors is performed by incubating at 37 ℃ for 20 minutes to ensure adequate inhibition of ACE activity.
In a preferred embodiment, when the ACE inhibitory peptides are screened, the peptides with ACE inhibitory function can induce aggregation of AuNPs and have purple color, while the peptides without ACE inhibitory function can not induce aggregation of AuNPs and have red color; the 9 different active peptides were KAFAF, CAAAA, VPP, IPP, RPP, IPA, LEP, LQP and GSH, respectively, and the concentrations of the 9 active peptides were all 15 μ M.
The ACE activity is detected by an assembly sensor containing polypeptide-mediated AuNPs, and the Cys-ang (I) -Cys peptide based on angiotensin I is designed, each end of the peptide is connected with a cysteine, the cysteine contains a sulfydryl and can be connected to the AuNPs through an Au-S bond, so that the Cys-ang (I) -Cys peptide can induce the assembly of the AuNPs, and due to the Surface Plasmon Resonance (SPR) characteristic of the AuNPs, the dispersed AuNPs and the aggregated AuNPs show different Surface Plasmon Resonance (SPR) absorption in solution and are accompanied by color change which can be visually observed by naked eyes. Cys-Ang (I) -Cys peptide can gather on the surface of AuNPs at two ends through Au-S bonds and stimulate the gathering of the AuNPs to be purple or blue, and after ACE is introduced, the Cys-Ang (I) -Cys peptide is hydrolyzed, and sulfhydryl is dissociated from one end of the peptide, so that the AuNPs are dispersed and red. By realizing hydrolysis of ACE catalytic peptide and assembly/decomposition of AuNPs mediated by peptide, ACE detection is carried out in a rapid and direct mode, and the plasma biosensor can also be used for screening high-selectivity ACE inhibitors and developing antihypertensive drugs in consideration of the inhibitory effect of the ACE inhibitors on the ACE catalytic activity.
As shown in fig. 2: hair brushBright UV-visible spectrum shows that as the ACE concentration is increased from 5mU/mL to 60mU/mL, the SPR absorption peak is red-shifted and the solution gradually turns red, A 580 /A 520 Values are used to evaluate the aggregation status of AuNPs for ACE detection, according to A 580 /A 520 Values for ACE detection were linear ranging from 5-40mU/mL, R2 ═ 0.9743, and detection limit of ACE was 0.40mU/mL (S/N ═ 3).
The plasma nanosensor was further used to detect the ACE inhibitor ramipril because they can inhibit the enzymatic activity of ACE, resulting in the peptide inducing aggregation of AuNPs, which changed from red to blue after the ACE inhibitor was added, indicating that ACE-catalyzed hydrolysis was inhibited, the remaining Cys-ang (i) -Cys causing aggregation of AuNPs, a 580 /A 520 The values increased with increasing ramipril concentration and ACE activity was completely inhibited when the ramipril concentration reached 31.62 μ M, the median Inhibitory Concentration (IC) of ramipril 50 Value) was 6.65. mu.M, as shown in FIG. 3.
The points to be finally explained are: first, in the description of the present application, it should be noted that, unless otherwise specified and limited, the terms "mounted," "connected," "connecting," and "connecting" should be understood broadly, and may be a mechanical connection or an electrical connection, or a communication between two elements, and may be directly connected, and "upper," "lower," "left," and "right" are only used to indicate relative positional relationships, and when the absolute position of the object to be described is changed, the relative positional relationships may be changed;
secondly, the method comprises the following steps: in the drawings of the disclosed embodiment of the invention, only the structures related to the disclosed embodiment are related, other structures can refer to common design, and the same embodiment and different embodiments of the invention can be combined mutually under the condition of no conflict;
and finally: the above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the present invention, and any modifications, equivalents, improvements and the like made within the spirit and principle of the present invention should be included in the scope of the present invention.
Claims (8)
1. A method for detecting angiotensin converting enzyme, comprising:
when the ACE activity is detected, diluting ACE in deionized water to a final concentration of 0.5mU/L to 60mU/L, wherein each 96-well plate contains ACE 25 mU L, Cys-ang (I) -Cys peptide 40mU L, incubating at 37 ℃ to ensure that the Cys-ang (I) -Cys peptide is fully hydrolyzed, then adding 50 mU L AuNPs into the 96-well plate, amplifying an ACE activity signal by detecting the residual quantity of the Cys-ang (I) -Cys peptide, and finally recording the ultraviolet visible absorption spectrum of the AuNPs solution in the range of 400-800nm within 5 min;
before the ACE activity is detected, AuNPs need to be synthesized, and the synthesis method of the AuNPs comprises the following steps:
100 ml of 1mM chloroauric acid was weighed into a round-bottom flask, heated to 120 ℃ by continuous stirring, then 10 ml of 38.8mM sodium citrate solution was added rapidly and continuously to ensure complete reduction of chloroauric acid, which when the solution turned from colorless to deep red, indicated the formation of AuNPs, the heat was removed and the AuNPs were cooled at room temperature and ready for use.
2. The method for detecting angiotensin converting enzyme according to claim 1 wherein: before the ACE activity is detected, Cys-Ang (I) -Cys peptide is used for inducing aggregation of AuNPs, Cys-Ang (I) -Cys peptide with different concentrations is added into 150 mu L of deionized water, then 50 mu L of AuNPs is added, after 5 minutes of equilibrium, AuNPs solution is aggregated to different degrees due to Au-S interaction, the color of the AuNPs solution changes from red to blue or purple along with the increase of the concentration of the Cys-Ang (I) -Cys peptide, then the solution is further analyzed and characterized by utilizing ultraviolet-visible spectrum, dynamic light scattering and a transmission electron microscope, and the concentration of the Cys-Ang (I) -Cys peptide added into each 96-well plate is determined to be 5mu M.
3. The method for detecting angiotensin converting enzyme according to claim 1 wherein: the incubation time at 37 ℃ was 30 minutes when the ACE activity was measured.
4. The method for detecting angiotensin converting enzyme according to claim 1 wherein: and removing a heat source in the ACE synthetic process, cooling, and removing larger impurities in AuNPs by adopting a polyether sulfone membrane to obtain the AuNPs required by the experiment.
5. The method for detecting angiotensin converting enzyme according to claim 2 wherein: the addition amount of Cys-Ang (I) -Cys peptide is 50 μ L when the Cys-Ang (I) -Cys peptide is used for inducing aggregation of AuNPs, so that the final volume in a 96-plate hole is 250 μ L, and the concentration range of Cys-Ang (I) -Cys peptide in different concentrations in the 96-plate hole is 0-1000 nM.
6. Use of a method for the detection of angiotensin converting enzyme according to any of claims 1 to 5 wherein:
(I): detecting ACE inhibitor, mixing 40 μ L ACE with 40 μ L enalapril and ramipril with different concentrations, incubating at 37 deg.C, adding Cys-Ang (I) -Cys peptide 40 μ L and deionized water 30 μ L, testing the rest ACE activity according to the method for detecting ACE activity, adding 50 μ L AuNPs as signal amplification tool, and detecting the ACE inhibitory activity by adopting 400-800nm AuNPs ultraviolet-visible absorption spectrum;
(II): screening ACE inhibitory peptides, incubating 9 different active peptides with 30mU/mL ACE in deionized water for 15 min, adding 5 μ M Cys-Ang (I) -Cys to react with inactivated ACE at 37 deg.C for 15 min, adding 50 μ L AuNPs to 150 μ L mixture, and screening out polypeptides with ACE inhibitory activity by color change.
7. The use of a method according to claim 6 for the detection of angiotensin converting enzyme wherein: the incubation time at 37 ℃ for the detection of the ACE inhibitor is 20 minutes, which ensures that the ACE activity is sufficiently inhibited.
8. The use of a method according to claim 6 for the detection of angiotensin converting enzyme wherein: when the ACE inhibitory peptides are screened, the peptides with the ACE inhibitory function can induce AuNPs to gather and are purple, while the peptides without the ACE inhibitory function can not induce AuNPs to gather and are red; the 9 different active peptides were KAFAF, CAAAA, VPP, IPP, RPP, IPA, LEP, LQP and GSH, respectively, and the concentrations of the 9 active peptides were all 15 μ M.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110611018.5A CN113324933B (en) | 2021-06-01 | 2021-06-01 | Method for detecting angiotensin converting enzyme and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110611018.5A CN113324933B (en) | 2021-06-01 | 2021-06-01 | Method for detecting angiotensin converting enzyme and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113324933A CN113324933A (en) | 2021-08-31 |
| CN113324933B true CN113324933B (en) | 2022-07-26 |
Family
ID=77423199
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110611018.5A Active CN113324933B (en) | 2021-06-01 | 2021-06-01 | Method for detecting angiotensin converting enzyme and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113324933B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020252365A1 (en) * | 2019-06-14 | 2020-12-17 | Bloodworks | Systems and methods to predict increased risk for adverse cardiovascular events in human immunodeficiency virus (hiv)-infected subjects |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101408509B (en) * | 2008-10-27 | 2010-07-14 | 中国科学技术大学 | Aminothiopropionic acid fast detecting method based on gold nano particle colloidal sols absorption spectrum |
| CN102426157B (en) * | 2011-11-16 | 2013-02-27 | 江南大学 | Method for analyzing tyrosinase activity based on functional Au nanoparticles |
| CN103063597B (en) * | 2013-01-09 | 2014-12-31 | 南京工业大学 | Method for detecting lipase activity |
| CN103149167A (en) * | 2013-02-26 | 2013-06-12 | 上海交通大学 | Method for detecting tetracycline residues in milk and drinking water |
| US10443049B2 (en) * | 2017-01-24 | 2019-10-15 | Northwestern University | Active low molecular weight variants of angiotensin converting enzyme 2 (ACE2) |
-
2021
- 2021-06-01 CN CN202110611018.5A patent/CN113324933B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020252365A1 (en) * | 2019-06-14 | 2020-12-17 | Bloodworks | Systems and methods to predict increased risk for adverse cardiovascular events in human immunodeficiency virus (hiv)-infected subjects |
Non-Patent Citations (3)
| Title |
|---|
| An optical biosensing platform for proteinase activity using gold nanoparticles;Chuang YC,et al.;《Biomaterials》;20100831;第31卷(第23期);全文 * |
| Interaction of gold nanoparticles mediated by captopril and S-nitrosocaptopril: the effect of manganese ions in mild acid medium;Iglesias E,et al.;《PHYSICAL CHEMISTRY CHEMICAL PHYSICS》;20141107;第17卷(第1期);全文 * |
| 基于金纳米粒子修饰石墨烯碳糊电极的同型半胱氨酸电化学传感;张靖芳 等;《分析科学学报》;20200630;第36卷(第6期);全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113324933A (en) | 2021-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xue et al. | Aggregation-induced emission enhancement of gold nanoclusters triggered by silicon nanoparticles for ratiometric detection of protamine and trypsin | |
| Sun et al. | Fluorescence immunoassay system via enzyme-enabled in situ synthesis of fluorescent silicon nanoparticles | |
| Mao et al. | Multidimensional colorimetric sensor array for discrimination of proteins | |
| Kaur et al. | Trypsin detection strategies: a review | |
| Kilian et al. | Peptide-modified optical filters for detecting protease activity | |
| Shamsipur et al. | Indirect colorimetric detection of glutathione based on its radical restoration ability using carbon nanodots as nanozymes | |
| Hu et al. | Highly sensitive fluorescent detection of trypsin based on BSA-stabilized gold nanoclusters | |
| Song et al. | Label-free fluorescence assay for protein kinase based on peptide biomineralized gold nanoclusters as signal sensing probe | |
| Ding et al. | Colorimetric protease assay by using gold nanoparticles and oligopeptides | |
| Gong et al. | Recent advances and perspectives of enzyme-based optical biosensing for organophosphorus pesticides detection | |
| CN105693703B (en) | A kind of novel Ratiometric fluorescent probe for the imaging of intracellular lysosomal pH | |
| Kim et al. | Gold nanoparticles-based colorimetric assay for cathepsin B activity and the efficiency of its inhibitors | |
| Zhang et al. | Simple and sensitive fluorescence assay for acetylcholinesterase activity detection and inhibitor screening based on glutathione-capped gold nanoclusters | |
| Wang et al. | A fluorescence sensor for protein kinase activity detection based on gold nanoparticles/copper nanoclusters system | |
| Rawat et al. | Colorimetric and fluorescence “turn-on” methods for the sensitive detection of bromelain using carbon dots functionalized gold nanoparticles as a dual probe | |
| Su et al. | A bio-inspired plasmonic nanosensor for angiotensin-converting enzyme through peptide-mediated assembly of gold nanoparticles | |
| Kaur et al. | An anionic tetraphenyl ethylene based simple and rapid fluorescent probe for detection of trypsin and paraoxon methyl | |
| Rajapaksha et al. | Review on the recent progress in the development of fluorescent probes targeting enzymes | |
| Deng et al. | Fluorescent gold nanocluster-based sensor for detection of alkaline phosphatase in human osteosarcoma cells | |
| Lv et al. | A gold nanoparticle based colorimetric and fluorescent dual-channel probe for acetylcholinesterase detection and inhibitor screening | |
| Wang et al. | A novel sensing platform for the determination of alkaline phosphatase based on SERS-fluorescent dual-mode signals | |
| Pu et al. | Recent progress in sensor arrays using nucleic acid as sensing elements | |
| Jiang et al. | A facile nanozyme based catalytic platform for the selective and sensitive detection of thrombin | |
| Wang et al. | In situ synthesis of fluorescent copper nanoclusters for rapid detection of ascorbic acid in biological samples | |
| Chen et al. | A general colorimetric method for detecting protease activity based on peptide-induced gold nanoparticle aggregation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |